The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
 
Piyush Grover
No Relationships to Disclose
 
Isabel Li
No Relationships to Disclose
 
Anke Kuijpers
No Relationships to Disclose
 
Firas Y. Kreidieh
No Relationships to Disclose
 
Andrew Williamson
No Relationships to Disclose
 
Teresa Maria Santos Amaral
Honoraria - Novartis
Consulting or Advisory Role - CeCaVa
Research Funding - NeraCare GmbH (Inst); Novartis (Inst); Skyline Diagnostics (Inst)
 
Florentia Dimitriou
Honoraria - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Sun Pharma
 
Joanna Placzke
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; MSD Oncology; Novartis; Pierre Fabre
 
Kelly Olino
No Relationships to Disclose
 
Maria Grazia Vitale
No Relationships to Disclose
 
Philippe Saiag
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche/Genentech; Sanofi
Research Funding - Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; pierre fabre; Roche
 
Ralf Gutzmer
Honoraria - Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - 4SC; Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma
Research Funding - Almirall Hermal GmbH (Inst); Amgen (Inst); Kyowa Kirin (Inst); Merck Serono (Inst); Novartis (Inst); Sanofi (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Pierre Fabre; Sun Pharma
 
Clara Allayous
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Roger Olofsson Bagge
Stock and Other Ownership Interests - SATMEG Ventures
Consulting or Advisory Role - BD Bard; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Roche
Research Funding - BMS (Inst); Endomagnetics; Skyline Diagnostics (Inst)
 
Nethanel Asher
No Relationships to Disclose
 
Tarek Meniawy
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; GlaxoSmithKline; MSD; Novartis; Regeneron; Sanofi
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Serono (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Aleigha Lawless
No Relationships to Disclose
 
Lydia Warburton
Consulting or Advisory Role - Bristol Myers Squibb Foundation; MSD Oncology; Novartis
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Innovent Biologics; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Provectus; QBiotics; Regeneron